drugset / Trial / NCT00003508
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
NaSingle-groupOpen-labelTreatment
Summary
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Mesothelioma.
Timeline
- Start
- 1996-03-08
- Primary completion
- 2005-04-26
- Completion
- 2005-04-26
Publications
- Background Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in advanced malignant mesothelioma: A strategy for improved survival. Journal of Cancer Therapy. 2014; 5:1127-1144.
- Background Burzynski SR, Lewy RI, Axler M, Janicki TJ.Treatment of malignant mesothelioma (MM) with sodium phenylbutyrate.Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Astugenal | Unknown | — | Intravenous |
| Subject | antineoplaston A10 | Small molecule | — | Intravenous |